ArticlePloS one2008
Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 61 citations in OpenAlex.
- Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026Review
- Damage-induced IL-18 stimulates thymic NK cells limiting endogenous tissue regeneration.Nature immunology · 2025Article
- Interleukin Networks in GVHD: Mechanistic Crosstalk, Therapeutic Targeting, and Emerging Paradigms.International journal of molecular sciences · 2025Review
- Challenges and future perspectives for high-throughput chimeric antigen receptor T cell discovery.Current opinion in biotechnology · 2024Review
- The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion.Nature communications · 2024Article
- Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.Journal for immunotherapy of cancer · 2024Article
- Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential.Cancers · 2023Review
- Chimeric antigen receptor T cells therapy in solid tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Insights into mechanisms of graft-versus-host disease through humanised mouse models.Bioscience reports · 2022Review
- Obesity-related IL-18 Impairs T-Regulatory Cell Function and Promotes Lung Ischemia-Reperfusion Injury.American journal of respiratory and critical care medicine · 2021Article
- Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction.Frontiers in immunology · 2021Review
- Review
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nature reviews. Clinical oncology · 2020Review
- Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GCancers · 2020Article
- Gut microbiome and CAR-T therapy.Experimental hematology & oncology · 2019Review
- Engineering CAR-T Cells for Improved Function Against Solid Tumors.Frontiers in immunology · 2018Review
- Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.Cell reports · 2017Article
- Role of interleukin-18 in the pathophysiology of allergic diseases.Cytokine & growth factor reviews · 2016Review
- Functional Mechanisms of Treg in the Context of HIV Infection and the Janus Face of Immune Suppression.Frontiers in immunology · 2016Review
- Switching off malignant pleural effusion formation-fantasy or future?Journal of thoracic disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
IL-18 has pleotropic effects on the activation of T cells during antigen presentation. We investigated the effects of human IL-18 on the engraftment and function of human T cell subsets in xenograft mouse models. IL-18 enhanced the engraftment of human CD8(+) effector T cells and promoted the development of xenogeneic graft versus host disease (GVHD). In marked contrast, IL-18 had reciprocal effects on the engraftment of CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) in the xenografted mice. Adoptive transfer experiments indicated that IL-18 prevented the suppressive effects of Tregs on the development of xenogeneic GVHD. The IL-18 results were robust as they were observed in two different mouse strains. In addition, the effects of IL-18 were systemic as IL-18 promoted engraftment and persistence of human effector T cells and decreased Tregs in peripheral blood, peritoneal cavity, spleen and liver. In vitro experiments indicated that the expression of the IL-18Ralpha was induced on both CD4 and CD8 effector T cells and Tregs, and that the duration of expression was less sustained on Tregs. These preclinical data suggest that human IL-18 may have use as an adjuvant for immune reconstitution after cytotoxic therapies, and to augment adoptive immunotherapy, donor leukocyte infusions, and vaccine strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.